Cost-effectiveness of rapid assessment of potential ischaemic heart disease with CT coronary angiography.
Praveen ThokalaSteve GoodacreKatherine OateyRachel O'BrienDavid E NewbyAlasdair GrayPublished in: Heart (British Cardiac Society) (2023)
There are no demonstrable differences in within-trial costs and QALYs, and long-term cost-effectiveness modelling suggested higher long-term costs with CTCA and uncertain effect on long-term QALYs, making routine use of CTCA for suspected ACS unlikely to be a cost-effective use of NHS resources.
Keyphrases
- acute coronary syndrome
- computed tomography
- study protocol
- patient safety
- pulmonary hypertension
- phase iii
- clinical practice
- randomized controlled trial
- contrast enhanced
- magnetic resonance imaging
- dual energy
- risk assessment
- positron emission tomography
- magnetic resonance
- loop mediated isothermal amplification
- double blind
- placebo controlled